The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIMI Regulatory News (IMI)

Share Price Information for IMI (IMI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,874.00
Bid: 1,882.00
Ask: 1,884.00
Change: -6.00 (-0.32%)
Spread: 2.00 (0.106%)
Open: 1,863.00
High: 1,888.00
Low: 1,863.00
Prev. Close: 1,880.00
IMI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Interim Management Statement

4 Nov 2021 07:00

RNS Number : 2680R
IMI PLC
04 November 2021
 

4 November 2021

Good Q3 progress prompts increase in full year EPS guidance to 88p to 92pGrowth and profitability initiatives continue to build momentum

IMI, the specialist engineering company, issues the following Interim Management Statement, which covers results for the third quarter from 1 July to 30 September 2021. 

Roy Twite, Chief Executive, commented:

"Trading in the third quarter has been somewhat ahead of our previous expectations and, while markets and supply chains continue to be volatile, demand into the first few weeks of the final quarter remains good.  We therefore now increase our guidance for full year EPS to 88p to 92p (from 85p to 90p), subject to no material change in trading conditions. Our programmes to reduce complexity, improve customer service, and deliver [Breakthrough Engineering for a better world] through accelerated market-led innovation are progressing at pace. We remain confident in our ability to deliver over time sustainable, profitable growth, including the growth and margin ambitions described in our recent Capital Markets Events."

 

Current trading

Given the exceptional circumstances of 2020, we continue to include 2019 detail in this statement. References to organic changes are on a constant currency basis and exclude disposals and acquisitions. References to adjusted figures reflect figures as reported to management which exclude the impact of adjusting items.

IMI Group

Q3 2021

Q3 2021

vs Q3 2020

Q3 2021

vs Q3 2019

Revenue & organic change

£453m

+6%

+5%

The third quarter of 2021 has delivered another good performance with Group sales and operating profits both higher organically than the same period in the prior year and 2019, despite Q3 2020 being the peak period for ventilator surge sales last year. IMI organic revenues in the three months to the end of September were 6% higher than the same period in 2020 and 1% higher on an adjusted basis.

Our various initiatives to put the customer at the centre of our organisation, to reduce complexity and to drive growth through market-led innovation are progressing at pace. We continue to strengthen our customer relationships and reputation for close support, especially on those occasions when customers have faced particular pressures, including in the supply chain.

We constantly monitor rising input costs and remain confident that our own efficiency improvements and pricing actions will allow us to absorb any impact, enabling IMI to achieve the further margin expansion we target - despite the increased levels of investment for growth.

Outlook

Based on current market conditions we now expect 2021 full year adjusted EPS to be in the range of 88p to 92p. This guidance reflects our expected average share position in 2021 of approximately 267 million shares, resulting from the ongoing share buyback. IMI remains on track to complete the planned £200 million buyback by the end of 2021.

IMI Precision Engineering

IMI Precision

Q3 2021

Q3 2021

vs Q3 2020

Q3 2021

vs Q3 2019

Revenue & organic change

£229m

+3%

+6%

 

IMI Precision organic revenues in the three months to the end of September were 3% higher than the same period in 2020 and 2% lower on an adjusted basis.

Sales in both Industrial Automation and Commercial Vehicle continued to be strong in the period, which more than offset the reduction within Life Science as a result of the Coronavirus-related surge in ventilator components sales in the prior period. We still expect that this surge will represent a headwind to full year 2021 results of approximately £75m to £80m.

Based on current market conditions, IMI Precision Engineering 2021 organic revenues and margins are still expected to be higher than in 2020.

IMI Critical Engineering

IMI Critical

Q3 2021

Q3 2021

vs Q3 2020

Q3 2021

vs Q3 2019

Order intake & organic change

£136m

+14%

-15%

Revenue & organic change

£137m

+4%

0%

 

IMI Critical order intake in the three months to the end of September totalled £136m, or 14% above the prior year, but 15% below the same period in 2019. Year to date, divisional orders remain 6% higher than prior year, supported by strong Aftermarket activity across a number of segments.

IMI Critical organic revenues in the three months to the end of September of £137m were 4% higher, and on an adjusted basis were 1% lower, than the third quarter of 2020. The drive to maximise the Aftermarket opportunity whilst positioning for growth in new, adjacent segments, is progressing well.

Regarding the 20% to 30% of IMI Critical Engineering that has been 'under review', after careful consideration the Board has taken the decision to retain and develop this business. Its performance has improved significantly over the last 18 months, supported by the development of upgrade Aftermarket opportunities within the installed base of products. In addition, the business has secured early orders in the attractive growth market of liquid Hydrogen processing, based upon expertise IMI previously developed and successfully deployed into space propulsion systems. Over time, there is now a clear path to the achievement of divisional target returns and long-term growth potential.

Based on the division's order book and current market conditions, we continue to expect IMI Critical Engineering 2021 organic revenues and margins to be higher when compared to 2020.

 

IMI Hydronic Engineering

IMI Hydronic

Q3 2021

Q3 2021

vs Q3 2020

Q3 2021

vs Q3 2019

Revenue & organic change

£87m

+14%

+10%

 

IMI Hydronic revenues in the three months to the end of September were 14% higher on an organic and 11% higher on an adjusted basis, when compared to last year. While installer and distributor catch-up persist as supporting influences on volumes, underlying demand remains good and the contribution from sales of new products continues to be positive.

Given current market conditions, IMI Hydronic Engineering's 2021 organic revenues are still expected to be strongly ahead, with margins also higher, when compared to 2020.

 

Coronavirus update

Although in some economies Coronavirus-related pressures are easing, IMI continues to be vigilant across its operations. The protection of our employees, our operations and our broader communities, wherever in the world they may be, remains an absolute priority. The Coronavirus response team continues to support employee welfare and help mitigate disruption in our supply chains. We continue to keep particularly close to our customers, to support them as they face all such challenges.

 

Share buyback progress

The programme to buy back IMI shares to an approximate value of £200m has made good progress. As at the end of October, we had successfully purchased 9.7 million shares, at a cost of £165m.

Exchange rates

The 2021 full year financial results are expected to be impacted by exchange rates. Should the rates in early November continue for the remainder of the year, results for both revenue and profits in the full year would be adversely impacted by 4%-5%.

Preliminary 2021 results

IMI will issue its preliminary results announcement for the year ending 31 December 2021 on 25 February 2022.

Enquiries to:

John Dean

IMI

Tel: +44 (0)121 717 3712

Stephen Malthouse

Headland PR

Tel: +44 (0)7734 956 201

A conference call for analysts and investors will be held at 08:00 GMT today to discuss this statement. To access the call, please register using the link: https://www.incommglobalevents.com/registration/client/9139/imi%E2%80%99s-interim-management-statement/

Notes to editors

IMI plc, the specialist engineering company, designs, manufactures and services highly engineered products that control the precise movement of fluids. Its innovative technologies, built around valves and actuators, enable vital processes to operate safely, sustainably, cleanly, efficiently and cost effectively. IMI employs around 10,000 people, has manufacturing facilities in 18 countries and operates a global service network. The Company is listed on the London Stock Exchange. Further information is available at www.imiplc.com.

 

IMI plc is registered in England No. 714275. Its legal entity identifier ('LEI') number is 2138002W9Q21PF751R30.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTUPGAAGUPGGQW
Date   Source Headline
3rd Aug 20209:28 amRNSTotal Voting Rights
28th Jul 202011:33 amRNSDirector/PDMR Shareholding
24th Jul 20207:00 amRNSInterim results, six months ended 30 June 2020
17th Jul 20209:36 amRNSDirector/PDMR Shareholding - Replacement
15th Jul 20202:32 pmRNSDirector/PDMR Shareholding
2nd Jul 202011:37 amRNSBlock listing Interim Review
1st Jul 202010:30 amRNSTotal Voting Rights
10th Jun 202011:06 amRNSDirector/PDMR Shareholding
1st Jun 20209:11 amRNSTotal Voting Rights
20th May 20201:57 pmRNSHolding(s) in Company
13th May 20202:06 pmRNSDirector/PDMR Shareholding
7th May 20201:04 pmRNSResult of AGM
7th May 20207:00 amRNSInterim Management Statement & Coronavirus update
1st May 202010:03 amRNSTotal Voting Rights
30th Apr 20204:48 pmRNSHolding(s) in Company
27th Apr 20205:27 pmRNSDisclosure of rights attached to equity shares
21st Apr 20201:07 pmRNSChange of Venue for the 2020 AGM
21st Apr 202012:30 pmRNSDirector Declaration
16th Apr 20204:26 pmRNSHolding(s) in Company
15th Apr 20202:20 pmRNSDirector/PDMR Shareholding
14th Apr 20204:42 pmRNSDirector/PDMR Shareholding
1st Apr 20209:56 amRNSTotal Voting Rights
30th Mar 20207:00 amRNSCoronavirus update
26th Mar 20203:58 pmRNSHolding(s) in Company
18th Mar 20204:56 pmRNSDirector/PDMR Shareholding
17th Mar 20204:37 pmRNSDirector/PDMR Shareholding
12th Mar 202010:52 amRNSDirector/PDMR Shareholding
11th Mar 202012:18 pmRNSDirector/PDMR Shareholding
2nd Mar 20203:10 pmRNSTotal Voting Rights
28th Feb 20207:00 amRNSPreliminary results, year ended 31 December 2019
12th Feb 20203:07 pmRNSDirector/PDMR Shareholding
3rd Feb 202010:55 amRNSTotal Voting Rights
15th Jan 202012:15 pmRNSDirector/PDMR Shareholding
13th Jan 20203:31 pmRNSHolding(s) in Company
3rd Jan 202011:54 amRNSBlock listing Interim Review
2nd Jan 20202:04 pmRNSTotal Voting Rights
11th Dec 20192:40 pmRNSDirector/PDMR Shareholding
2nd Dec 201910:20 amRNSTotal Voting Rights
27th Nov 20199:00 amRNSNon-executive director changes
21st Nov 20198:10 amRNSDirector/PDMR Shareholding
14th Nov 201910:04 amRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSIMS and Strategy Review conclusions
1st Nov 201910:04 amRNSTotal Voting Rights
9th Oct 20192:07 pmRNSDirector/PDMR Shareholding
1st Oct 201910:17 amRNSTotal Voting Rights
23rd Sep 20197:00 amRNSCompletion of PBM acquisition
16th Sep 20193:51 pmRNSDirector/PDMR Shareholding
11th Sep 20191:08 pmRNSDirector/PDMR Shareholding
2nd Sep 201910:18 amRNSTotal Voting Rights
20th Aug 20197:00 amRNSProposed acquisition of PBM for $85m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.